Welcome to our dedicated page for Hologic SEC filings (Ticker: HOLX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Hologic, Inc. (Nasdaq: HOLX) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures filed with the U.S. Securities and Exchange Commission. As a Delaware corporation with common stock registered under Section 12(b) of the Exchange Act and listed on The Nasdaq Stock Market LLC, Hologic submits periodic and current reports that offer detailed insight into its operations, financial performance and material corporate events.
Among the most closely watched documents for Hologic are its annual reports on Form 10-K and quarterly reports on Form 10-Q, which describe the company’s diagnostics, breast health, GYN surgical and skeletal health businesses, outline risk factors and discuss segment performance. Current reports on Form 8-K provide timely updates on specific events, such as quarterly earnings releases, changes to executive compensation arrangements and material transactions.
Recent 8-K filings have included the announcement of financial results for the fourth quarter of fiscal 2025, along with reconciliations of non-GAAP measures such as adjusted EBITDA and non-GAAP EPS, and the disclosure of a revised form of restricted stock unit award agreement approved by the Compensation Committee. Another 8-K details the Agreement and Plan of Merger under which a merger subsidiary affiliated with funds managed by Blackstone and TPG will merge with and into Hologic, with Hologic surviving as a wholly owned subsidiary of a parent entity. That filing also notes that, if the merger is consummated, Hologic’s common stock will be delisted from Nasdaq and deregistered under the Exchange Act.
On this page, users can review Hologic’s 8-K filings related to transaction announcements, executive employment agreement amendments and results of operations, alongside its periodic reports when available. These filings help investors understand how Hologic’s diagnostics, breast health, GYN surgical and skeletal health segments contribute to overall results, how non-GAAP metrics are defined, and how material agreements—such as the proposed merger with Blackstone- and TPG-affiliated entities—may affect the company’s capital structure and listing status.
Stock Titan enhances access to these documents by pairing them with AI-powered summaries that explain key points in plain language. This can be especially helpful for lengthy filings like 10-K and 10-Q reports, as well as complex transaction-related 8-Ks. Users interested in HOLX can use this page to monitor new filings as they appear on EDGAR, review historical disclosures and track how Hologic’s regulatory reporting reflects developments in its medical technology and women’s health businesses.
Hologic (HOLX) reported insider activity by its Chief Operating Officer. On November 10, 2025, the officer was granted 47,106 restricted stock units that vest in equal installments on each of the first three anniversaries of the grant date. The filing also shows share withholdings to cover taxes: 3,927 shares on November 7, 2025 and 1,701 shares on November 11, 2025, both coded “F.” After the reported transactions, the officer directly owned 78,952 shares. The RSUs settle one-for-one in common stock.
Hologic (HOLX) reported insider activity by its General Counsel. On November 10, 2025, the officer received 17,496 restricted stock units that vest in equal installments on each of the first three anniversaries of the grant date. Shares were withheld to cover taxes upon RSU settlement: 288 shares at $74.10 on November 7 and 406 shares at $74.60 on November 11. Following these transactions, direct ownership stood at 28,574 shares. This total includes 346 shares acquired through the employee stock purchase plan since the prior report.
Hologic, Inc. announced a governance update related to equity compensation. On November 4, 2025, the company’s Compensation Committee approved a revised form of Restricted Stock Unit (RSU) Award Agreement, adopted for fiscal 2026. The revised agreement is provided as Exhibit 10.1 to the report and incorporated by reference. This is an administrative update to the standard documentation governing future RSU grants and does not disclose financial terms or changes to award amounts.
Hologic (HOLX) reported insider activity by its Chairman, President and CEO. On 11/04/2025, the executive acquired 83,589 shares of common stock designated as performance stock units, for which performance criteria have been satisfied but that remain subject to service-based vesting. Following the transaction, directly owned shares totaled 1,318,213. Indirect holdings were 1,146,829 shares through the MacMillan Family Trust.
The total includes 1,079,673 restricted/performance stock units whose settlement has been deferred under the company’s Deferred Equity Plan. Performance stock units settle one-for-one into common stock.
Hologic, Inc. (HOLX) reported an insider equity change by a company officer (Group President, International). On 11/04/2025, the officer acquired 15,196 shares of common stock, tied to performance stock units where the performance criteria have been met but the award remains subject to service-based vesting. Following this transaction, the officer beneficially owns 119,010 shares, held directly. The filing notes that performance stock units settle into common stock on a one-for-one basis.
Hologic (HOLX) reported an insider equity update. The Chief Financial Officer filed a Form 4 showing an acquisition of 17,095 performance stock units on 11/04/2025 (transaction code A). These units have met performance criteria and remain subject to service-based vesting, and are settled one-for-one in common stock. Following the transaction, the officer beneficially owned 119,203 shares, which includes 41,121 RSUs/PSUs with settlement deferred under the company’s Deferred Equity Plan. Ownership is listed as direct.
Hologic, Inc. (HOLX) Chief Operating Officer reported an equity acquisition on 11/04/2025 via Form 4. The filing shows 9,116 shares of common stock acquired (Code A), which the footnotes describe as performance stock units for which performance criteria have been satisfied but that remain subject to service-based vesting. These units settle into common stock on a one-for-one basis.
Following the reported transaction, the executive beneficially owned 37,474 shares, held directly. The filing also notes that this total includes 401 shares acquired through the issuer’s employee stock purchase plan since the executive’s most recent report.
Hologic (HOLX) reported an insider equity change by its officer, the President, Breast & Skeletal. On 11/04/2025, the reporting person acquired 2,278 shares of common stock (code A). The filing notes these relate to performance stock units for which performance criteria were met but that remain subject to service-based vesting, and such units are settled one-for-one in common stock.
Following the reported transaction, the reporting person beneficially owned 9,681 shares directly. This figure includes 346 shares acquired under the employee stock purchase plan since the prior report and 2,327 restricted stock units whose settlement has been deferred under the Issuer’s Deferred Equity Plan.
Hologic (HOLX) reported an insider equity change: the company’s Principal Accounting Officer acquired 2,656 shares of common stock on 11/04/2025, reported on Form 4. Following this transaction, the reporting person beneficially owns 14,283 shares.
The filing notes these were performance stock units for which performance criteria were met, and they remain subject to service-based vesting. The units are settled in common stock on a one-for-one basis. The ownership total includes 377 shares acquired through the company’s employee stock purchase plan.
Hologic, Inc. (HOLX) furnished its Q4 financial results via a press release for the quarter ended September 27, 2025. The release was provided under Item 2.02 and is attached as Exhibit 99.1. The company noted that this information is furnished, not filed, and included standard cautionary language regarding forward‑looking statements.
Hologic also referenced a proposed acquisition by affiliates of Blackstone Inc. and TPG Capital. The company plans to file and mail a definitive Proxy Statement to stockholders in connection with the proposed transaction and urged investors to review those materials when available at the SEC’s website and Hologic’s investor relations page.
FAQ
What is the current stock price of Hologic (HOLX)?
What is the market cap of Hologic (HOLX)?
